Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer | Zendy

Ronan J. Kelly | Zendy; Jaffer A. Ajani | Zendy; Jarosław Kużdżał | Zendy; Thomas Zander | Zendy; Eric Van Cutsem | Zendy; Guillaume Piessen | Zendy; Guillermo Méndez | Zendy; Josephine Feliciano | Zendy; Satoru Motoyama | Zendy; Astrid Lièvre | Zendy; Hope E. Uronis | Zendy; Elena Elimova | Zendy; Cecile Grootscholten | Zendy; Karen Geboes | Zendy; S. Yousuf Zafar | Zendy; Stephanie Snow | Zendy; Andrew H. Ko | Zendy; Kynan Feeney | Zendy; Michael Schenker | Zendy; Piotr Kocoń | Zendy; Jenny Zhang | Zendy; Li Zhu | Zendy; Ming Lei | Zendy; Prianka Singh | Zendy; Kaoru Kondo | Zendy; James M. Cleary | Zendy; Markus Moehler | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Author(s) -

Ronan J. Kelly,

Jaffer A. Ajani,

Jarosław Kużdżał,

Thomas Zander,

Eric Van Cutsem,

Guillaume Piessen,

Guillermo Méndez,

Josephine Feliciano,

Satoru Motoyama,

Astrid Lièvre,

Hope E. Uronis,

Elena Elimova,

Cecile Grootscholten,

Karen Geboes,

S. Yousuf Zafar,

Stephanie Snow,

Andrew H. Ko,

Kynan Feeney,

Michael Schenker,

Piotr Kocoń,

Jenny Zhang,

Li Zhu,

Ming Lei,

Prianka Singh,

Kaoru Kondo,

James M. Cleary,

Markus Moehler

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2032125

Subject(s) - gastroesophageal junction , nivolumab , medicine , esophageal cancer , adjuvant , chemoradiotherapy , oncology , esophagectomy , cancer , gastroenterology , adenocarcinoma , immunotherapy

No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or gastroesophageal junction cancer.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research